Co-Diagnostics, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Co-Diagnostics submitted FDA 510(k) and CLIA Waiver for Co-Dx PCR Flu A/B RSV test (clinical study: 1,400+ patients, 27 analytical studies, 10,000+ test runs). Company completed $3.0M at-the-market private placement. Q2 2026: revenue $0.17M (vs $0.16M YoY), operating loss $6.2M (vs $8.1M), net loss $6.3M ($1.46/share), cash fell from $11.9M (Dec 2025) to $3.6M (June 2026)—a 69% decline in six months. Expanded operations in Saudi Arabia (CoMira facility lease), Mexico distribution, India TB studies, and Vector Smart to 21 U.S. states.
Why this rating
510(k) filing is major regulatory milestone for $10M-cap biotech; cash burn ($8.2M H1) is alarming but typical for early-stage; $3M raise insufficient for runway. Material development but survival-dependent on execution.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.